ライフサイエンスコーパス: hydrocortisone

1 of a physiological dose of 4 mg of cortisol (hydrocortisone).

2 y (ie, methotrexate with both cytarabine and hydrocortisone).

3 oxacin plus dexamethasone, and neomycin plus hydrocortisone.

4 C) in high-risk patients can be reduced with hydrocortisone.

5 ortisone + placebo, or 4) triiodothyronine + hydrocortisone.

6 in the total brain volume was observed with hydrocortisone.

7 blocked the volume reduction associated with hydrocortisone.

8 ation before and 24 hours after the start of hydrocortisone.

9 icoids; this T-cell response was hindered by hydrocortisone.

10 Performance on the CVLT was not affected by hydrocortisone.

11 ls in the presence of cytokines, stroma, and hydrocortisone.

12 inephrine > or = 1,25-(OH)(2) vitamin D(3) > hydrocortisone.

13 tients with adrenal failure not treated with hydrocortisone.

14 d is suppressed by topical administration of hydrocortisone.

15 continued within 24 hrs of the first dose of hydrocortisone.

16 amin plus hydrocortisone versus placebo plus hydrocortisone.

17 ck-dependent hydrocortisone compared with no hydrocortisone.

18 ts withdrew consent for 1 child treated with hydrocortisone.

19 loxacin plus dexamethasone) or neomycin plus hydrocortisone.

20 o two groups, based on the administration of hydrocortisone.

21 were randomly assigned to receive placebo or hydrocortisone (0.5 mg/kg twice per day for 7 days, foll

22 Hydrocortisone (0.6 mg/mice i.p.) was administered immed

23 ceive clobetasol propionate, 0.05% cream, or hydrocortisone, 1%, cream.

24 All patients were administered hydrocortisone (100 mg every 8 hrs) for the first 24 hrs

25 erioperative high-dose corticosteroids (HDS; hydrocortisone, 100 mg, intravenously 3 times daily, fol

26 Participants received hydrocortisone (160 mg/day)/placebo, phenytoin/placebo,

27 t infection, mice were treated with low dose hydrocortisone (2 mg/kg/) i.p. on alternate days.

28 ohn's disease were randomized to intravenous hydrocortisone 200 mg or placebo immediately before thei

29 d, double-blind, placebo-controlled trial of hydrocortisone (200 mg/d for 7 d) in patients with sever

30 re a memory encoding task; 2) received 10 mg hydrocortisone 210 minutes (slow cortisol) before a memo

31 ed to one of three groups: 1) received 10 mg hydrocortisone 30 minutes (rapid cortisol effects) befor

32 gether with K (400 mg orally [p.o.] tid) and hydrocortisone (30 mg p.o. each morning, 10 mg p.o. each

33 r resuscitation was treated with stress-dose hydrocortisone (300 mg daily for 7 days maximum and grad

34 A dose of hydrocortisone (4 microg/kg/min for 6 hrs) that maintain

35 fusion titrated up to 0.06 U/min and then IV hydrocortisone (50 mg 6 hourly) or placebo.

36 pants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143)

37 receive parenteral ascorbic acid (1500 mg), hydrocortisone (50 mg), and thiamine (100 mg) every 6 ho

38 amin plus hydrocortisone versus placebo plus hydrocortisone, a posttherapy decline in PSA of > or = 5

39 WT), severe combined immunodeficient (SCID), hydrocortisone acetate (HC)-treated WT, and HC-treated S

40 on.The aim of this study was to confirm that hydrocortisone acetate (HC-ac) ophthalmic ointments of 2

41 r efficacy than a control group treated with Hydrocortisone acetate 0.5% therapy.

42 Hydrocortisone acetate 2.5% and Hydrocortisone acetate 1% eye ointments are efficacious

43 Hydrocortisone acetate 2.5% and Hydrocortisone acetate 1

44 2 weeks after test dosing, and also received hydrocortisone, acyclovir, and Bactrim or equivalent pro

45 n were reduced in a dose-dependent manner by hydrocortisone added to cocultures.

46 ptic shock do not benefit from moderate-dose hydrocortisone administered to overcome etomidate-relate

47 There are few reports on hydrocortisone administration after cardiac arrest, and

48 e of infection, a protective effect of early hydrocortisone administration against unfavorable outcom

49 he results demonstrate a correlation between hydrocortisone administration and the high rates of surv

50 Hydrocortisone administration increases NOP receptor ava

51 This study aimed to evaluate the effect of hydrocortisone administration on the outcomes of patient

52 The high-dose hydrocortisone administration reduced the percent of spe

53 trial of suramin plus hydrocortisone versus hydrocortisone alone.

54 Hydrocortisone also led to diminished production of indu

55 one patients were allocated to vasopressin + hydrocortisone and 30 patients to vasopressin + placebo.

56 led that commonly used cell culture reagents hydrocortisone and cholera toxin shifted the cell popula

57 ssigned to DAA alone (24 mug/kg/h for 96 h), hydrocortisone and fludrocortisone alone, their respecti

58 in 128 of 181 infants (70.7%) randomized to hydrocortisone and in 140 of 190 infants (73.7%) randomi

59 the steroid antagonist mifepristone, whereas hydrocortisone and other steroids mimicked the effects o

60 ed the effect of exogenous administration of hydrocortisone and partially prevented the detrimental e

61 pocampus revealed no differences between the hydrocortisone and placebo conditions; however, post-cha

62 ficant differences were observed between the hydrocortisone and placebo groups for time until septic

63 Adding hydrocortisone and stromal cells greatly increases the f

64 These therapies include hydrocortisone and vasopressin.

65 neural level, the combined administration of hydrocortisone and yohimbine reduced the sensitivity of

66 rmed that the simultaneous administration of hydrocortisone and yohimbine renders instrumental behavi

67 ated in habit learning were not modulated by hydrocortisone and yohimbine.

68 ted by HG or high hydrocortisone (HC: 500 nM hydrocortisone) and was lower in heavier animals.

69 4 (95% CI, 1.32-2.85) for ciprofloxacin plus hydrocortisone, and 2.00 (95% CI, 1.18-3.41) for ciprofl

70 4 (95% CI, 1.03-4.85) for ciprofloxacin plus hydrocortisone, and 2.30 (95% CI, 1.09-4.87) for ciprofl

71 triple therapy (ITT) including methotrexate, hydrocortisone, and cytarabine would improve the postind

72 nized the effects of the GCs corticosterone, hydrocortisone, and prednisolone, but not the synthetic

73 cts of pharmacotherapies (eg, beta blockers, hydrocortisone, and selective serotonin re-uptake inhibi

74 line) were grown to confluence, primed with hydrocortisone, and then exposed to the PRLs.

75 recommends the use of docetaxel, prednisone/hydrocortisone, and/or mitoxantrone in specific settings

76 eceive a 42-hr continuous infusion of either hydrocortisone at 200 mg/day (HC group; n = 49) or salin

77 ritically Ill Patients with Septic Shock and hydrocortisone at a 50 mg IV bolus every 6 hr and fludro

78 Adjunctive hydrocortisone therapy (hydrocortisone at a dose of 200 mg/d for 7 d for Adjunct

79 Specifically, administration of hydrocortisone at doses analogous to those achieved unde

80 acute tympanostomy-tube otorrhea to receive hydrocortisone-bacitracin-colistin eardrops (76 children

81 ated very preterm infants, administration of hydrocortisone between 7 and 14 days after birth, compar

82 bine (increasing noradrenergic stimulation), hydrocortisone, both substances, or a placebo to healthy

83 compared with immature enterocytes and that hydrocortisone can accelerate this maturational process.

84 baseline (BASE) and following an intravenous hydrocortisone challenge (CORT) in 19 healthy control su

85 ear drops were ofloxacin, ciprofloxacin plus hydrocortisone, ciprofloxacin plus dexamethasone, and ne

86 decrease in CT-clathrin colocalization in H4/hydrocortisone compared with H4 cells by electron micros

87 rval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone.

88 th severe sepsis not in septic shock, use of hydrocortisone compared with placebo did not reduce the

89 hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulte

90 D-19 and acute respiratory failure, low-dose hydrocortisone, compared with placebo, did not significa

91 was on average 11% to 16% higher in the post-hydrocortisone condition compared with the baseline cond

92 Hydrocortisone could transiently correct hypoglycemia in

93 or three small solutes-water, L-glucose, and hydrocortisone-covering a wide range of membrane permeab

94 igned to receive a 22-day course of systemic hydrocortisone (cumulative dose, 72.5 mg/kg) (n = 182) o

95 study in patients with trauma, we found that hydrocortisone decreased the blood level of interleukin-

96 Patients treated with hydrocortisone demonstrated a significantly greater redu

97 ylation and CD23 expression in monocytes and hydrocortisone-dependent IgE switching in B cells.

98 cids only in the high insulin group, however hydrocortisone did not affect the levels of acyl carniti

99 ithout adrenal insufficiency, treatment with hydrocortisone did not affect vasopressor dose at 24 hrs

100 esults show that testosterone, estrogen, and hydrocortisone did not alter basal CatSper currents, whe

101 Of patients who survived to have their hydrocortisone dose changed, 57% had their corticosteroi

102 the group that received the 4 microg/kg/min hydrocortisone dose.

103 sepsis, a 5- to 7-day course of physiologic hydrocortisone doses with subsequent tapering increases

104 randomized to receive one of three different hydrocortisone doses, by intravenous infusion, for 6 hrs

105 foration between quinolone and neomycin plus hydrocortisone ear drop-exposed children.

106 , adrenal insufficiency must be treated with hydrocortisone early in life.

107 r-alpha was lower among patients who had had hydrocortisone early.

108 progesterone equivalent (PEQ) and 13.5 ng/l hydrocortisone equivalent (HEQ).

109 00 mg (range, 50-267 mg of hydrocortisone or hydrocortisone equivalent for dexamethasone); the median

110 85 mg (range, 50-890 mg of hydrocortisone or hydrocortisone equivalent for prednisone).

111 r low-dose corticosteroids (LDS; intravenous hydrocortisone equivalent to presurgical oral dosing, fo

112 day; P = 0.01), and in lower total dosages (hydrocortisone equivalents, 1209 mg vs. 23 975 mg; P = 0

113 ges in the hippocampal volume during a brief hydrocortisone exposure and whether volumetric changes c

114 ermia, helium, surfactant, glucose, insulin, hydrocortisone, fluid resuscitation and fluid removal, s

115 o receive a continuous infusion of 200 mg of hydrocortisone for 5 days followed by dose tapering unti

116 In patients receiving hydrocortisone for septic shock, early initiation of tre

117 These findings do not support the use of hydrocortisone for this indication.

118 ly adverse effect reported more often in the hydrocortisone group (18.2%) than in the placebo group (

119 lacebo group 167 +/- 286; triiodothyronine + hydrocortisone group 466 +/- 495; p = 0.20).

120 (93%; 46% female) were evaluated (194 in the hydrocortisone group and 185 in the placebo group) at a

121 t failure events, including 11 deaths in the hydrocortisone group and 20 deaths in the placebo group.

122 ccurred in 36 of 170 patients (21.2%) in the hydrocortisone group and 39 of 170 patients (22.9%) in t

123 oth in the entire group and the suramin plus hydrocortisone group at all three landmarks in both univ

124 rface area with hair loss, compared with the hydrocortisone group at all time points except at 6 week

125 occurred in 32 of 76 patients (42.1%) in the hydrocortisone group compared with 37 of 73 (50.7%) in t

126 ma vasopressin levels were not higher in the hydrocortisone group compared with the placebo group (64

127 The hydrocortisone group had a significantly higher survival

128 The hydrocortisone group required a shorter duration of vaso

129 ere neurodevelopmental impairment (7% in the hydrocortisone group vs 11% in the placebo group) was no

130 ld neurodevelopmental impairment (20% in the hydrocortisone group vs 18% in the placebo group), or wi

131 ut neurodevelopmental impairment (73% in the hydrocortisone group vs 70% in the placebo group), with

132 cantly different between groups (91.7 in the hydrocortisone group vs 91.4 in the placebo group; betwe

133 therapy (3.1 d; 95% CI, 1.1-5.1; shorter in hydrocortisone group) and required a lower total dose of

134 d DGE (29% vs 44%) tended to be lower in the hydrocortisone group.

135 For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ su

136 s in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively.

137 shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and

138 s, n = 46) and those with late initiation of hydrocortisone (> 9 hr after vasopressors, n = 124).

139 Hydrocortisone had a concentration greater than a human-

140 In contrast, hydrocortisone had no effect on metabolic parameters.

141 Of 48 patients who completed both courses, hydrocortisone had no significant effect on outcome; how

142 olunteers at baseline, and after intravenous hydrocortisone (HC) administered at moderate (250 mg) an

143 oid fibroblasts, and the altered response to hydrocortisone (HC) and differential regulation of a sub

144 Elimination of hydrocortisone (HC) from EN2 reduced the mean neurites p

145 (to inhibit adrenal cortisol secretion) + /- hydrocortisone (HC) in a randomised crossover design to

146 We have shown previously that hydrocortisone (HC) induces IgE synthesis in IL-4-stimul

147 KEY POINTS: Hydrocortisone (HC) is required for activation of large-

148 he present study we investigated the role of hydrocortisone (HC) on uridine-5'-triphosphate (UTP)-sti

149 own in standard culture medium or induced by hydrocortisone (HC).

150 Lipolysis was not stimulated by HG or high hydrocortisone (HC: 500 nM hydrocortisone) and was lower

151 e administered exogenous synthetic cortisol (hydrocortisone, HCT) using two different dosing regimens

152 severe sepsis and septic shock treated with hydrocortisone, high-dose ascorbic acid, and thiamine (H

153 The potency of 3 was similar to that of hydrocortisone (IC(50) = 0.01 microM), although 3 does n

154 Trials of galantamine, hydrocortisone, IgG, valganciclovir, isoprinosine, fluox

155 The [(11)C]NOP-1A and hydrocortisone imaging paradigm should allow for the exa

156 The precise mechanism of hydrocortisone immune regulation in the management of co

157 dritic cell by natural killer cells and that hydrocortisone improves outcome by limiting this immunos

158 quence furnished 1 in 11% overall yield from hydrocortisone in 15 linear steps.

159 Hydrocortisone in a dose of 200 mg/day in four divided d

160 l pressure (1C); avoiding use of intravenous hydrocortisone in adult septic shock patients if adequat

161 ined whether including a physiologic dose of hydrocortisone in dexamethasone treatment can reduce neu

162 sessment of the neurodevelopmental safety of hydrocortisone in extremely preterm infants.

163 ner following stimulation with prolactin and hydrocortisone in HC11 cells expressing human PR-B.

164 /m(2), oral estramustine, and low-dose daily hydrocortisone in men with HRPC who demonstrated progres

165 The efficacy of hydrocortisone in patients with severe sepsis without sh

166 ethylprednisolone during CPR and stress-dose hydrocortisone in postresuscitation shock, compared with

167 udy was to identify prescribing triggers for hydrocortisone in septic shock.

168 A randomized trial of stress-dose hydrocortisone in TBI patients with AI is underway.

169 on and after the administration of 100 mg of hydrocortisone in the patients (P</=0.03 for both compar

170 These findings do not support the use of hydrocortisone in these patients.

171 Treatment of primary TE monolayers with hydrocortisone in vitro induced expression of involucrin

172 counteracted the immunosuppressive effect of hydrocortisone in vivo.

173 nistering triiodothyronine, with and without hydrocortisone, in a model of septic shock.

174 nfusion of triiodothyronine, with or without hydrocortisone, in an ovine model of septic shock did no

175 by competition with exogenous bile acids and hydrocortisone, in contrast to progesterone, which produ

176 The highest dose of hydrocortisone increased plasma BCAs in both insulin gro

177 Treatment of thymic organ cultures with hydrocortisone induced both medullary and subcapsular co

178 Low dose hydrocortisone induced significant upregulation of a sub

179 The primary outcome measure was hydrocortisone-induced DeltaV(T) calculated as (V(T CORT

180 Hydrocortisone-induced DeltaV(T) was significantly negat

181 radioactive xenon washout technique after a hydrocortisone infusion (2 mg/kg per min for 16 h) or sa

182 n = 33) or high-dose (0.45 mg/kg IV; n = 33) hydrocortisone infusion.

183 in nondiabetic human subjects: 1) antecedent hydrocortisone infusions (simulating physiologic cortiso

184 iological concentrations of testosterone and hydrocortisone inhibited CatSper activation by progester

185 Hydrocortisone is increasingly used as an alternative, b

186 Stimulation with both prolactin and hydrocortisone is required for the induction of these lo

187 ock with differential treatment responses to hydrocortisone is unknown.Objectives: To determine if th

188 Hydrocortisone led to an acute increase in plasma cortis

189 es as tracers; plasma clearance of 100 mg of hydrocortisone; levels of urinary cortisol metabolites;

190 of specific conditions, we suggest using IV hydrocortisone < 400 mg/day for >/= 3 days at full dose

191 divided into those with early initiation of hydrocortisone (< 9 hr after vasopressors, n = 46) and t

192 d immunosuppression, we investigated whether hydrocortisone modulates the dendritic cell/natural kill

193 in and placebo (n = 104), norepinephrine and hydrocortisone (n = 101), or norepinephrine and placebo

194 vasopressin (titrated up to 0.06 U/min) and hydrocortisone (n = 101), vasopressin and placebo (n = 1

195 ock was clinically evident) (n = 152), or no hydrocortisone (n = 108).

196 ents were randomized to receive suramin plus hydrocortisone (n = 229) or placebo plus hydrocortisone

197 lus hydrocortisone (n = 229) or placebo plus hydrocortisone (n = 231).

198 1072 neonates screened, 523 were assigned to hydrocortisone (n = 256) or placebo (n = 267) and 406 su

199 Patients were randomized to receive low-dose hydrocortisone (n = 76) or placebo (n = 73).

200 either cortisol (single oral dose of 100 mg hydrocortisone, N = 34) or testosterone (three doses of

201 In a second step, the effects of hydrocortisone on dendritic cell/natural killer cell cro

202 mine if there is heterogeneity in effect for hydrocortisone on mortality, shock resolution, and other

203 was no heterogeneity in effect of adjunctive hydrocortisone on mortality, shock resolution, or other

204 ystemic vascular resistance (2C); and use of hydrocortisone only in children with suspected or proven

205 Specifically, GR agonists hydrocortisone or dexamethasone inhibited p53-dependent

206 tive GC dose was 100 mg (range, 50-267 mg of hydrocortisone or hydrocortisone equivalent for dexameth

207 fter surgery was 485 mg (range, 50-890 mg of hydrocortisone or hydrocortisone equivalent for predniso

208 h 90-day mortality and treatment with either hydrocortisone or placebo for total cortisol (odds ratio

209 nts were randomly assigned to receive either hydrocortisone or placebo in a circadian rhythm (10 mg/m

210 8 and 30 years of age received either 100 mg hydrocortisone or placebo on separate occasions approxim

211 ere was an interaction between assignment to hydrocortisone or placebo, and SRS endotype (P = 0.02).

212 ve norepinephrine or vasopressin followed by hydrocortisone or placebo.

213 treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortiso

214 ome devaluation (and thus habitual), whereas hydrocortisone or yohimbine alone have no such effect.

215 ake inhibitor reboxetine (RBX), (3) 30 mg of hydrocortisone, or (4) both drugs in combination.

216 re quinolones (ofloxacin, ciprofloxacin plus hydrocortisone, or ciprofloxacin plus dexamethasone) or

217 The addition of adrenaline, noradrenaline, hydrocortisone, or dexamethasone to lipopolysaccharide-a

218 riiodothyronine + placebo group 501 +/- 370; hydrocortisone + placebo group 167 +/- 286; triiodothyro

219 + placebo, 2) triiodothyronine + placebo, 3) hydrocortisone + placebo, or 4) triiodothyronine + hydro

220 were measured at 6-12 and 24-36 hours after hydrocortisone/placebo administration.

221 eive in total 8 doses of randomization-based hydrocortisone/placebo every 8 hours.

222 ized trial, investigated whether intravenous hydrocortisone premedication can reduce ATI.

223 Intravenous hydrocortisone premedication significantly reduces ATI l

224 interaction between HC and insulin was that hydrocortisone produced an elevation in levels of BCAs a

225 rapies in the prevention of PTSD or ASD, but hydrocortisone reduced the risk of developing PTSD.

226 ant, sleep-related difficulties, addition of hydrocortisone reduced total sleeping problems and disor

227 Hydrocortisone reduces the rate of pneumonia in patients

228 interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credibl

229 t dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of

230 hormones estradiol and progesterone, whereas hydrocortisone served as a substrate of only AcrAB-TolC.

231 t treatment exists in the form of thyroxine, hydrocortisone, sex steroids, growth hormone, and desmop

232 propose that 11betaHSD2-sensitive GCs (e.g., hydrocortisone) should be used in preference to dexameth

233 Hydrocortisone showed a large effect in reducing the ris

234 unological category, both immunoglobulin and hydrocortisone showed some limited effects but, overall,

235 However, hydrocortisone significantly increased GM1/lipid raft as

236 with IT triples (ITT) (MTX, cytarabine, and hydrocortisone sodium succinate [HSS]) as presymptomatic

237 Results showed that hydrocortisone spared the pulmonary neutrophilia but res

238 Hydrocortisone spared vasopressin requirements, reduced

239 ctional groups attached to the D-ring of the hydrocortisone steroid molecule produces compounds with

240 nt psychosocial adverse effects, addition of hydrocortisone substantially reduced their Strength and

241 nt study examined the effect of two doses of hydrocortisone (synthetic cortisol) administration on au

242 thiobenzothiazole-containing derivatives of hydrocortisone (termed MS4 and MS6) were examined using

243 Under moderate-dose hydrocortisone the autobiographical memory performance d

244 Healthy participants were administered hydrocortisone, the alpha2-adrenoceptor antagonist yohim

245 Adjunctive hydrocortisone therapy (hydrocortisone at a dose of 200

246 To assess whether early hydrocortisone therapy in extremely preterm infants is a

247 Objective: To determine whether hydrocortisone therapy in patients with severe sepsis pr

248 Importance: Adjunctive hydrocortisone therapy is suggested by the Surviving Sep

249 osteroids for Human Septic Shock, adjunctive hydrocortisone therapy showed a 90-day monetized benefit

250 y Ill Patients with Septic Shock, adjunctive hydrocortisone therapy showed a 90-day monetized benefit

251 Using adjunctive hydrocortisone therapy yields a significant monetized be

252 total estimated annual impact of adjunctive hydrocortisone therapy, in 2019 dollars, was $2.3 billio

253 total estimated annual impact of adjunctive hydrocortisone therapy, in 2019 dollars, was $750 millio

254 estimate the budget impact using adjunctive hydrocortisone therapy, per-patient avoided cost was mul

255 monstrating an immune regulatory response to hydrocortisone therapy, potentially by stabilization of

256 suppressed further by increasing the dose of hydrocortisone to 8 microg/kg/min, although the mean pea

257 ts suggest that adding a physiologic dose of hydrocortisone to dexamethasone treatment can reduce the

258 ary analysis of the PREMILOC (Early Low-Dose Hydrocortisone to Improve Survival without Bronchopulmon

259 rs, with 1,000 units of heparin and 20 mg of hydrocortisone to reduce the incidence of thrombosis and

260 he Surviving Sepsis Campaign suggests giving hydrocortisone to septic patients only if their "blood p

261 rial, ATI levels were lower at week 16 among hydrocortisone-treated patients (1.6 vs. 3.4 microg/mL,

262 1.6 vs. 3.4 microg/mL, P = 0.02), and 26% of hydrocortisone-treated patients developed ATI compared w

263 nfected chronic granulomatous disease (CGD), hydrocortisone-treated, and neutropenic mice.

264 Hydrocortisone treatment did not alter trypsinogen relea

265 rtisol breakdown affects the optimum dose of hydrocortisone treatment during critical illness.

266 Early low-dose hydrocortisone treatment has been reported to improve su

267 Hydrocortisone treatment reduced this suppressive functi

268 tokines IFN gamma, TNFalpha IL-17 and IL-10, hydrocortisone treatment significantly reduced colonic p

269 erall PPDC can be significantly reduced with hydrocortisone treatment.

270 erapeutic responders and those refractory to hydrocortisone treatment.

271 Hydrocortisone use was associated with increased mortali

272 ac arrest to discharge, stratified by use of hydrocortisone, using a Japanese health-insurance claims

273 accomplished from the commercially available hydrocortisone utilizing Hg(II)-catalyzed spiroketalizat

274 multicenter randomized trial of suramin plus hydrocortisone versus hydrocortisone alone.

275 rospective, randomized trial of suramin plus hydrocortisone versus placebo plus hydrocortisone, a pos

276 a randomized phase III trial of suramin plus hydrocortisone versus placebo plus hydrocortisone.

277 h at 36 weeks' postmenstrual age (15.5% with hydrocortisone vs 23.7% with placebo; risk difference, -

278 icant differences, including BPD (55.2% with hydrocortisone vs 50.0% with placebo; risk difference, 5

279 In the hydrocortisone vs placebo groups, 21.5% vs 16.9% had sec

280 he setting of pneumovirus infection in vivo, hydrocortisone was administered to mice infected with pn

281 However, hydrocortisone was associated with a significant 1.69% r

282 s with adrenal insufficiency, treatment with hydrocortisone was associated with a significant reducti

283 ision to treat patients with stress doses of hydrocortisone was at the discretion of the treating int

284 Intra-venous hydrocortisone was given, however, his recovery was not

285 In addition, the administration of hydrocortisone was independent predictor of survival to

286 of extremely preterm infants, early low-dose hydrocortisone was not associated with a statistically s

287 erleukin-10 level in natural killer cells by hydrocortisone was partially dependent on the up-regulat

288 re already receiving two vasopressors before hydrocortisone was prescribed.

289 hock in whom vasopressors were initiated and hydrocortisone was prescribed.

290 ppressive medications were discontinued, and hydrocortisone was started.

291 Hydrocortisone was used as a challenge because in microd

292 In addition, hydrocortisone was used as a potent intestinal trophic f

293 assette and its up-regulation by insulin and hydrocortisone was verified by in vitro transfection.

294 with septic shock treated with low doses of hydrocortisone were enrolled.

295 stimulated cells with or without addition of hydrocortisone) were analyzed for the expression of gluc

296 PVM-infected mice responded to hydrocortisone with enhanced viral replication and accel

297 sed risk for TMP compared with neomycin plus hydrocortisone, with an adjusted hazard ratio of 2.26 (9

298 as earlier among patients with initiation of hydrocortisone within 9 hours.

299 colitis and failed to respond to intravenous hydrocortisone within about 5 days.

300 triple IT drug (methotrexate, cytarabine and hydrocortisone) without CRT.